Chordia Therapeutics (TSE:190A) EV-to-EBITDA : -12.49 (As of May. 31, 2025)

Chordia Therapeutics EV-to-EBITDA Chart

Competitive Comparison of Chordia Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Chordia Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chordia Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chordia Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Chordia Therapeutics's EV-to-EBITDA falls into.

Chordia Therapeutics EV-to-EBITDA Calculation

Chordia Therapeutics's EV-to-EBITDA for today is calculated as:

Chordia Therapeutics's current Enterprise Value is 円12,384.39 Mil.
Chordia Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-991.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordia Therapeutics  (TSE:190A) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Chordia Therapeutics's PE Ratio (TTM) for today is calculated as:

Chordia Therapeutics's share price for today is 円227.00.
Chordia Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-16.890.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Chordia Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Chordia Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Chordia Therapeutics Business Description